A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes

NCT02814838 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Insulin-Dependent

Interventions

DRUG: Ladarixin
DRUG: Placebo

Sponsor

Dompé Farmaceutici S.p.A